Class | Brand | Generic | Indication | Dose Form | Route | Adult Dose | Ped. Dose | MOA |
Antiretroviral Agent; Protease Inhibitor | Prezista | Darunavir | HIV Infection | Oral Susp: 100mg/ml;
Oral Tablet:
75, 150, 400, 600, 800mg | Oral | Tx naive: 800mg with ritonavir 100mg QD with food; Tx experienced: 600mg with ritonavir 100mg BID | 3YO+: Tx with no darunavir resistance: darunavir 35mg/kg with ritonavir 7mg/kg QD; Tx with darunavir resistance: 20mg/kg with ritonavir 3mg/kg BID | HIV-1 protease inhibitor that prevents the cleavage of Gag and Gag-Pol polyprotein yielding immature, noninfectious virus |
Antirheumatic; Immune Modulator | Orencia | Abatacept | Juvenile idiopathic arthritis; RA (moderate to severe) | IV Powder for Soln:
250mg;
SubQ Soln:
125mg/ml | IV,
SubQ | SubQ: 125mg once weekly; IV: Initial dose, doses at week 2 and 4, then every 4 wk | 6YO+:
IV dose varies based on weight, same interval as adult | CTLA-4 Ig – demonstrates anti-inflammatory effects by down regulating T cell activation |
Bile Acid Sequestrant; Phosphate Binder | Renvela | Sevelamer | End Stage Renal Disease( hyperphosphatemia) | Oral Powder for Susp: 0.8gm/packet, 2.4gm/packet;Oral Tablet: 800mg | Oral | Varies based on serum phosphorus level
800-1600mg TID
w/ meals | N/A | Binds with phosphate molecules through ionic and hydrogen bonding and reduces phosphate absorption in the dietary tract, thereby lowering the serum phosphate concentration |
Cartilaginous Defect Repair Agent | Synvisc | Hyaluronate
(Hylan Polymers
A & B) | Osteoarthritis of knee | Inj. Soln:
8mg/ml | Intra-articularly | Inject 16mg(2mL) into the knee once weekly x 3 weeks | N/A
21YO+ | Derivative of the natural substance, hyaluronan, that lubricates and enables the joint to work properly |
Erythropoietic; Hematopoietic, Colony Stimulating Factor | Aranesp | Darbepoetin alfa | Anemia (due to chemotherapy or of chronic renal failure) | Inj. Soln:
many strengths
10mcg/0.4ml – 500mcg/ml | SubQ,
IV | once weekly dosing to every 3-week dosing | 1YO+:
Varies, once weekly - every 2 weeks | Binds to progenitor stem cells stimulating the production/
differentiation of RBCs |
Erythropoietic; Hematopoietic, Colony Stimulating Factor | Epogen; Procrit | Erythropoietin (Epoetin Alfa) | Anemia (due to chemo, chronic renal failure, zidovudine ADR); surgical procedure | Inj. Soln:
2000, 3000, 4000, 10000, 20000, 40000 (Procit only) U/ml | SubQ,
IV | 50-100 U/kg 3 times weekly; 40,000U/wk | Cancer patient 5YO+: 60,000 U/wk
; Dialysis pt 1MO+: 50U/kg 3x weekly | Stimulates the division and differentiation of committed erythroid progenitors in the bone marrow increasing RBC production |
Immunological Agent; Monoclonal Antibody | Herceptin | Trastuzumab | Breast cancer (HER2 overexpression); gastric cancer; malignant neoplasm of cardio-esophageal junction of stomach | IV Powder for Soln:
440mg | IV | BREAST CANCER(adjuvant Tx): 2-4mg/kg IV every 3 weeks; Breast cancer (metastatic): 2-4mg/kg/wk. GASTRIC CANCER: 6-8 mg/kg IV every 3 wks until disease progression. All are infused over 30-90 mins | N/A | Binds to extracellular domain of the HER2 protein which is overexpressed in 25-30% of primary breast cancers; inhibits the growth of tumor cells & mediates ADCC |
Monoclonal Antibody, Angiogenesis inhibitor, Vascular Endothelial Growth Factor (VEGF) inhibitor | Lucentis | Ranibizumab | Diabetic macular edema (DME); exudative age-related macular degeneration (AMD); macular retinal edema | Intraocular Soln: 0.3mg/0.05ml, 0.5mg/0.5ml | Intra-vitreal Injection | Dose varies
0.3-0.5 mg once a month | N/A | Inhibits the human VEGF-A by binding to its active forms thereby preventing ocular angiogenesis by VEGF-A |
Thyroid Supplement | Synthroid; Levoxyl; Levothroid; Unithroid; | Levothyroxine | Hypothyroidism; Myxedema coma; TSH suppression | IV Powder for Soln:
100, 200, 500mcg;
Oral Tablet:
25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300mcg | Oral, IV | 1.7mcg/kg/day. Severe: 12.5-25mcg/day; TSH suppression: 2mcg/kg/day | Hypothyrodism:
0mo-12yo:
10-3 mcg/kg/day | T3 and T4 are thought to act by binding to thyroid receptor proteins attached to DNA, thus activating gene transcription and protein synthesis |
Thyroid Supplement | Cytomel | Liothyronine | Hypothyroidism; Myxedema coma; Thyroid suppression; Simple Goiter | Oral Tablet:
5, 25, 50mcg
IV Soln:
10mcg/mL | Oral, IV | Hypothyroidism: 25-75mcg/day;
Myxedema; 50-100mcg/day | few months old: 20mcg/day; 1yo: 50 mcg/day; 3yo+: adult dosage | Synthetic natural thyroid hormone that stimulates O2 consumption by most body tissues. This accelerates BMR, and metabolism of carbs, proteins, and lipids. |
Thyroid Supplement | Armour Thyroid | Levothyroxine/Liothyronine (Thyroid) | Hypothyroidism; Thyroid stimulating hormone suppression | Oral Tablet:
15, 30, 60, 90, 120, 180, 240, 300mg | Oral | Initial Dose:
15-30mg/day
Maintenance: 60-120mg/day | 0mo-12yo+: 7.5-90mg/day | T3 and T4 are thought to act by binding to thyroid receptor proteins attached to DNA, thus activating gene transcription and protein synthesis |
Nonbarbiturate Hypnotic | Ambien; Ambien CR; Edluar; Intermezzo; Zolpimist | Zolpidem | Insomnia | Oral Tab:
5,10mg;
ER Tab:
6.25,12.5mg; SL Tab: Edluar: 5, 10mg, Intermezzo: 1.75, 3.5mg;
Oral Mist Spray: 5mg/0.1ml or 5mg/ACT; (AmbienPak:10mg/tab) | Oral, Sublingually | Intermezzo:1.75mg/women, 3.75 mg/men.
Women: 5mg, 6.25 mg . Men: 10mg, 12.5 mg
All are taken immediately before bedtime
USE LOWEST DOSE POSSIBLE | N/A | Binds the benzodiazepine (BZ) receptor subunit of the GABA-A receptor complex |
Nonbarbiturate Hypnotic | Lunesta | Eszopiclone | Insomnia | Oral Tablet: 1, 2, 3mg | Oral | 1-3 mg immediately before bedtime;
Max: 3mg | N/A | Believed to bind to or interact allosterically at the GABA-receptor complex domain |
Antibiotic, cyclic lipopeptide | Cubicin | Daptomycin | Bacteremia assoc. with intravascular line, bacteria due to S. aureus; infection of skin and/or subQ tissue; | IV Powder for Soln:
500mg | IV | skin infection: 4mg/kg/day x 7-14 days; Bacteremi(S.aureus): 6mg/kg/day x 2-6 wks; Bacteremia (MRSA): 6-8mg/kg/day | N/A | Binds to bacterial cell membranes and causes cell death by inducing rapid depolarization of the membrane potential, leading to disruption of DNA, RNA, and protein synthesis |
Antimetabolite; Antineoplastic Agent | Xeloda | Capecitabine | Colon cancer; metastatic breast cancer; metastatic colorectal cancer, Duke stage C colon cancer | Oral Tablet:
150, 500mg | Oral | 1250mg/m^2 BID x 2 wk, followed by 1 wk rest, then 3wk cycle (x total of 24 wks) | N/A | See Word Doc (too long) |
Antineoplastic Agent;
Tyrosine Kinase Inhibitor | Gleevec | Imatinib Mesylate | Leukemia (various forms); dermatofibrosarcoma protuberans; GI stromal tumor; hypereosinophilic syndrome; myelodysplastic syndrome (with PDGFR); myeloproliferative disorder (with PDGFR); systemic mast cell disease | Oral Tablet:
100, 400mg | Oral | 100-600mg QD | 1YO+
340mg/m^2 per day
Max: 600mg/day | Inhibits the bcr-abl tyrosine kinase and thus suppresses proliferation and promotes apoptosis in bcr-abl positive cell lines and fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia |
Antiretroviral, Reverse Transcriptase Inhibitor | Atripla | Efavirenz/ Emtricitabine/ Tenofovir | HIV infection | Oral Tablet:
600/200/300mg | Oral | 1 tab QD
on an empty stomach | 12YO+ and weigh 40kg:
1 tab QD
on an empty stomach | See Word Doc (too long) |
Antiretroviral, Reverse Transcriptase Inhibitor | Truvada | Emtricitabine/ Tenofovir | HIV Infection; also prophylaxis | Oral Tablet: 200/300mg | Oral | 1 tab QD on an empty stomach | 12YO+ and weigh 35kg+:
1 tab QD on an empty stomach | See Word Doc (too long) |
Antiretroviral; Antiviral; Protease Inhibitor | Reyataz | Atazanavir | HIV Infection | Oral Capsule:
150, 200, 300mg
Oral Packet:
50mg | Oral | Typical dose:
300mg with 100mg ritonavir QD w/ food
Patients who can't tolerate ritonavir: 400mg QD w/ food | 3Mo+:
Packet:
200-250mg
with 80 mg ritonavir QD w/food
6yo+: Cap: 150-300mg with 100mg ritonavir QD w/food
13yo+: and can't tolerate ritonavir: 400mg QD w/food | Azapeptide HIV-1 protease inhibitor, prevents formation of mature virions by selectively inhibiting the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells |
Antiretroviral Agent; Integrase Inhibitor | Isentress | Raltegravir | HIV Infection | Oral Tab: 400mg
Chewable Tab: 25, 100mg
Oral Powder for Suspension:
100mg/packet | Oral | 400mg BID | 4wk-older and <25kg:
Chewable: 75-150mg BID. Oral susp: 20-100mg BID
>25kg: 400mg tab BID
>25kg: chewable: 150-300mg BID | Inhibits viral DNA insertion into the host’s cellular genome; inhibits HIV-1 integrase inhibitor |